
AtriCure (ATRC) Stock Forecast & Price Target
AtriCure (ATRC) Analyst Ratings
Bulls say
AtriCure Inc reported a substantial revenue growth of 16.6% year-over-year in Q4 2024, reaching $124.3 million, which exceeded analysts' expectations. The company's investment in research and development increased significantly to 28.1% of sales, reflecting commitment to innovation, including a notable $12 million upfront payment for co-development of PFA products. Additionally, the EBITDA margin improved to 10.2%, indicating stronger operational efficiency and potential for enhanced profit generation, supporting a positive long-term financial outlook for the company.
Bears say
AtriCure Inc faces several risks that contribute to a negative outlook, including disappointing sales from its EPi-Sense/Convergent products, lower than anticipated sales in Open Ablation and AtriClip segments, and potential market share loss to Medtronic's offerings. Revenue growth has slowed, projected to decrease to less than 11%, driven by underperformance in Minimally Invasive Ablation, Appendage Management, and Pain Management sectors. Additionally, both gross and operating margins have declined year-over-year, with gross margins at 74.5%, falling short of consensus expectations, indicating ongoing challenges in profitability and operational efficiency.
This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.
AtriCure (ATRC) Analyst Forecast & Price Prediction
Start investing in AtriCure (ATRC)
Order type
Buy in
Order amount
Est. shares
0 shares